iMedic.health

NSAID: Class Overview and Comparison

Quick answer: NSAID are a class of medicines used for specific therapeutic indications. iMedic covers 14 nsaid substances. Below is a comparison table linking to detailed pages for each.

NSAID on iMedic (14 substances)

Substance Primary indications Mechanism Common dose
DexibuprofenMild to moderate pain, OsteoarthritisActive S(+)-enantiomer of ibuprofen that non-selectively inhibits COX-1 and COX-200-400 mg up to three times daily (max 1200 mg/day)
DiclofenacPain, InflammationNon-selective cyclooxygenase (COX-1/COX-2) inhibitor reducing prostaglandin synt50 mg 2-3 times daily or 75-150 mg/day
DicunoPain, InflammationDiclofenac brand — non-selective COX inhibitor reducing prostaglandin synthesis25-50 mg 2-3 times daily
FlurbiprofenPain, InflammationNon-selective COX-1 and COX-2 inhibitor reducing prostaglandin synthesis50-100 mg 2-4 times daily; lozenges 8.75 mg
IbudonPain, InflammationNon-selective COX inhibitor reducing prostaglandin synthesis (ibuprofen-based br200-400 mg every 4-6 hours
IbukronPain, InflammationNon-selective COX inhibitor reducing prostaglandin synthesis (ibuprofen-based br200-400 mg every 4-6 hours
IbumaxPain, InflammationNon-selective COX inhibitor reducing prostaglandin synthesis (ibuprofen-based br200-400 mg every 4-6 hours
IbunedPain, InflammationNon-selective COX inhibitor reducing prostaglandin synthesis (ibuprofen-based br200-400 mg every 4-6 hours
IbuprofenPain, InflammationNon-selective cyclooxygenase (COX-1/COX-2) inhibitor reducing prostaglandin synt200-400 mg every 4-6 hours (max 1200 mg/day OTC, 3200 mg/day Rx)
Ibuprofen FarmaliderPain, InflammationNon-selective COX inhibitor reducing prostaglandin synthesis (ibuprofen generic 200-400 mg every 4-6 hours
KetorolacShort-term management of moderate to severe acute painNon-selective cyclooxygenase inhibitor reducing prostaglandin synthesis10 mg orally every 4-6 hours; 15-30 mg IV/IM every 6 hours (max 5 days)
NaproxenPain, InflammationNon-selective COX-1/COX-2 inhibitor reducing prostaglandin synthesis250-500 mg twice daily
NurofenPain, FeverNon-selective COX-1 and COX-2 inhibitor reducing prostaglandin synthesis200-400 mg every 4-6 hours (max 1200 mg/day OTC)
TradilPain, InflammationNon-steroidal anti-inflammatory drug inhibiting cyclooxygenase enzymes (brand ofVaries by formulation

About NSAID

NSAID share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.

Common considerations across the class

Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.

Medical disclaimer: This tool provides educational information for general reference. It is not a substitute for professional medical advice, diagnosis, or treatment. Always discuss your individual situation with a qualified healthcare provider.

Frequently asked questions

What are NSAID?

NSAID are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 14 substances in this class with detailed pages for each.

Are all NSAID interchangeable?

No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.

How do I choose between different NSAID?

Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.

Are NSAID available as generics?

Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.

Last reviewed: by iMedic Medical Editorial Team. Our editorial process.